Amedisys, Inc. (NASDAQ:AMED) Given Consensus Rating of “Hold” by Brokerages

Amedisys, Inc. (NASDAQ:AMED) has been assigned an average recommendation of “Hold” from the five research firms that are covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $100.67.

A number of equities research analysts have recently issued reports on the company. William Blair cut Amedisys from an “outperform” rating to a “market perform” rating in a research note on Monday, July 1st. Cantor Fitzgerald reiterated a “neutral” rating and issued a $101.00 price target on shares of Amedisys in a research note on Thursday, July 25th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Amedisys from a “buy” rating to a “hold” rating and set a $101.00 target price on the stock. in a report on Monday, July 29th.

Hedge Funds Weigh In On Amedisys

Institutional investors and hedge funds have recently modified their holdings of the stock. Treasurer of the State of North Carolina increased its stake in shares of Amedisys by 1.0% during the fourth quarter. Treasurer of the State of North Carolina now owns 14,204 shares of the health services provider’s stock worth $1,350,000 after purchasing an additional 140 shares during the period. Arizona State Retirement System increased its position in Amedisys by 2.0% during the second quarter. Arizona State Retirement System now owns 9,145 shares of the health services provider’s stock worth $840,000 after acquiring an additional 177 shares during the period. Bridge City Capital LLC raised its stake in Amedisys by 0.8% in the 1st quarter. Bridge City Capital LLC now owns 29,861 shares of the health services provider’s stock worth $2,752,000 after purchasing an additional 231 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Amedisys by 0.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,199 shares of the health services provider’s stock valued at $2,876,000 after purchasing an additional 255 shares during the period. Finally, Creative Planning increased its holdings in shares of Amedisys by 7.4% during the second quarter. Creative Planning now owns 4,295 shares of the health services provider’s stock worth $394,000 after purchasing an additional 295 shares during the period. 94.36% of the stock is currently owned by institutional investors and hedge funds.

Amedisys Trading Down 0.3 %

NASDAQ AMED opened at $95.82 on Tuesday. The stock has a market capitalization of $3.13 billion, a price-to-earnings ratio of -149.72, a PEG ratio of 1.90 and a beta of 0.78. Amedisys has a 52 week low of $89.55 and a 52 week high of $98.95. The stock’s 50 day moving average price is $97.40 and its two-hundred day moving average price is $95.12. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.16 and a current ratio of 1.16.

Amedisys (NASDAQ:AMED) last announced its earnings results on Wednesday, July 24th. The health services provider reported $1.32 EPS for the quarter, topping the consensus estimate of $1.22 by $0.10. Amedisys had a net margin of 4.02% and a return on equity of 12.39%. The business had revenue of $591.19 million during the quarter, compared to analysts’ expectations of $579.34 million. As a group, analysts anticipate that Amedisys will post 4.66 earnings per share for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.